Efficacy and safety of infliximab therapy and predictors of response in korean patients with crohn’s disease: A nationwide, multicenter study

IBD Study Group of the Korean Association for the Study of the Intestinal Diseases

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated. Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis. Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.

Original languageEnglish
Pages (from-to)1376-1385
Number of pages10
JournalYonsei Medical Journal
Volume57
Issue number6
DOIs
Publication statusPublished - 2016 Nov 1

Fingerprint

Crohn Disease
Multicenter Studies
Safety
Therapeutics
Colonic Diseases
Infliximab
Pulmonary Tuberculosis
Referral and Consultation

Keywords

  • Crohn’s disease
  • Infliximab
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy and safety of infliximab therapy and predictors of response in korean patients with crohn’s disease : A nationwide, multicenter study. / IBD Study Group of the Korean Association for the Study of the Intestinal Diseases.

In: Yonsei Medical Journal, Vol. 57, No. 6, 01.11.2016, p. 1376-1385.

Research output: Contribution to journalArticle

IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. / Efficacy and safety of infliximab therapy and predictors of response in korean patients with crohn’s disease : A nationwide, multicenter study. In: Yonsei Medical Journal. 2016 ; Vol. 57, No. 6. pp. 1376-1385.
@article{f4e5f85f669b4f679715a9e7fdec4bec,
title = "Efficacy and safety of infliximab therapy and predictors of response in korean patients with crohn’s disease: A nationwide, multicenter study",
abstract = "Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated. Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2{\%} and 60.0{\%}, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2{\%} and 93.3{\%} at week 30 and 88.0{\%} and 77.0{\%} at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0{\%} and 56.2{\%} of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0{\%} and 97.1{\%}, respectively, at both week 30 and week 54. Thirty-nine patients (12.3{\%}) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0{\%}) patients including seven cases of active pulmonary tuberculosis. Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.",
keywords = "Crohn’s disease, Infliximab, Tuberculosis",
author = "{IBD Study Group of the Korean Association for the Study of the Intestinal Diseases} and Choi, {Chang Hwan} and Song, {In Do} and Kim, {Young Ho} and Koo, {Ja Seol} and Kim, {You Sun} and Kim, {Joo Sung} and Nayoung Kim and Kim, {Eun Soo} and Kim, {Jae Hak} and Kim, {Ji Won} and Kim, {Tae Oh} and Kim, {Hyun Soo} and Kim, {Hyo Jong} and Park, {Young Sook} and Park, {Dong Il} and Park, {Soo Jung} and Song, {Hyun Joo} and Shin, {Sung Jae} and Yang, {Suk Kyun} and Ye, {Byong Duk} and Lee, {Kang Moon} and Lee, {Bo In} and Lee, {Sun Young} and Lee, {Chang Kyun} and Im, {Jong Pil} and Jang, {Byung Ik} and Jeon, {Tae Joo} and Cho, {Yu Kyung} and Chang, {Sae Kyung} and Jeon, {Seong Ran} and Jung, {Sung Ae} and Jeen, {Yoon Tae} and Cha, {Jae Myung} and Han, {Dong Soo} and Kim, {Won Ho}",
year = "2016",
month = "11",
day = "1",
doi = "10.3349/ymj.2016.57.6.1376",
language = "English",
volume = "57",
pages = "1376--1385",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of infliximab therapy and predictors of response in korean patients with crohn’s disease

T2 - A nationwide, multicenter study

AU - IBD Study Group of the Korean Association for the Study of the Intestinal Diseases

AU - Choi, Chang Hwan

AU - Song, In Do

AU - Kim, Young Ho

AU - Koo, Ja Seol

AU - Kim, You Sun

AU - Kim, Joo Sung

AU - Kim, Nayoung

AU - Kim, Eun Soo

AU - Kim, Jae Hak

AU - Kim, Ji Won

AU - Kim, Tae Oh

AU - Kim, Hyun Soo

AU - Kim, Hyo Jong

AU - Park, Young Sook

AU - Park, Dong Il

AU - Park, Soo Jung

AU - Song, Hyun Joo

AU - Shin, Sung Jae

AU - Yang, Suk Kyun

AU - Ye, Byong Duk

AU - Lee, Kang Moon

AU - Lee, Bo In

AU - Lee, Sun Young

AU - Lee, Chang Kyun

AU - Im, Jong Pil

AU - Jang, Byung Ik

AU - Jeon, Tae Joo

AU - Cho, Yu Kyung

AU - Chang, Sae Kyung

AU - Jeon, Seong Ran

AU - Jung, Sung Ae

AU - Jeen, Yoon Tae

AU - Cha, Jae Myung

AU - Han, Dong Soo

AU - Kim, Won Ho

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated. Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis. Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.

AB - Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated. Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis. Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.

KW - Crohn’s disease

KW - Infliximab

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84986905870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986905870&partnerID=8YFLogxK

U2 - 10.3349/ymj.2016.57.6.1376

DO - 10.3349/ymj.2016.57.6.1376

M3 - Article

C2 - 27593865

AN - SCOPUS:84986905870

VL - 57

SP - 1376

EP - 1385

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -